Overview

The panic disorder market is gaining notable attention with rising awareness of mental health conditions and the increasing burden of anxiety-related disorders globally. In recent years, efforts to reduce stigma, improve diagnosis, and expand access to advanced treatment options have supported the market. Growing investments in drug development, therapy-based approaches, and healthcare infrastructure are further driving demand. A strong emphasis on early intervention programs and digital therapy solutions is strengthening the market outlook. With both pharmaceutical and non-pharmaceutical treatments advancing, the panic disorder market is poised for steady expansion across the 7 major markets.

Expert Market Research on Panic Disorder Market Size and Trends

Expert Market Research highlights that the panic disorder market size is on a steady upward path, reflecting both rising awareness and evolving treatment options. Growing acceptance of mental health therapies, combined with increasing demand for effective pharmaceutical and non-pharmaceutical solutions, is reshaping the market landscape. With consistent efforts to reduce stigma and expand healthcare access, the panic disorder market trends indicate significant potential for growth in the forecast period.

Market Size

The panic disorder market size in the 7 major markets reached USD 9.70 Billion in 2024, reflecting the increasing emphasis on mental health care. Growing awareness campaigns and accessibility to advanced treatment methods are fueling adoption. By 2034, the market is expected to reach USD 14.61 Billion, expanding at a CAGR of 4.18% during 2025-2034. This growth trajectory highlights the importance of innovative therapies and patient-centric approaches in managing panic disorder. Pharmaceutical companies and healthcare providers are increasingly focusing on introducing safer and more effective treatments, ensuring a positive market outlook over the forecast horizon.

Market Trends

The panic disorder market trends highlight a shift toward holistic treatments combining pharmacological and psychological approaches. Cognitive Behavioral Therapy (CBT) remains one of the most widely adopted non-drug therapies, while the demand for antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs) continues to expand. Emerging innovations in telemedicine and digital therapeutics are reshaping access to care, particularly post-pandemic. Pharmaceutical companies are investing in novel formulations with fewer side effects to improve compliance rates. Additionally, increasing collaborations between research institutes and drug developers are accelerating the launch of advanced treatment options. These trends signify a promising environment for the panic disorder market over the coming years.

Read Full report: https://www.expertmarketresearch.com/reports/panic-disorder-market/requestsample

Market Opportunities and Challenges

The panic disorder market presents significant opportunities driven by increasing mental health awareness campaigns, supportive government initiatives, and growing use of digital health tools. Expansion of healthcare facilities in emerging markets is creating new growth avenues. However, the market also faces challenges such as limited access to mental health professionals, social stigma in certain regions, and side effects of pharmacological treatments. High treatment costs and regulatory complexities for new drug approvals remain key barriers. Balancing these opportunities and challenges will determine how effectively stakeholders can sustain long-term growth in the panic disorder market.

Segmentation

Market Breakup by Type

• Agoraphobia
• Social Anxiety Disorder (SAD)
• Obsessive-Compulsive Disorder (OCD)
• Bipolar Disorder
• Post-Traumatic Stress Disorder (PTSD)
• Specific Phobias, Generalized Anxiety Disorder (GAD)
• Major Depressive Disorder (MDD)
• Others

Market Breakup by Therapy

• Electroconvulsive Therapy (ECT)
• Cognitive-Behavioral Therapy (CBT)

Market Breakup by Drug Class

• Benzodiazepines (BZD)
• Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
• Monoamine Oxidase Inhibitors (MAOIs)
• Anti-Depressants
• Tricyclic Antidepressants (TCAs)
• Pregabalin
• Buspirone
• Sertraline
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan

Growth

The panic disorder market growth is strongly supported by increasing government funding for mental health initiatives, rising insurance coverage for psychiatric treatments, and technological advancements in therapy delivery. Expansion of telepsychiatry and online counseling platforms has reduced geographical barriers, enabling patients to access therapy conveniently. Pharmaceutical advancements in anti-anxiety medications with improved tolerability profiles are also boosting acceptance. A growing number of clinical trials targeting panic disorder and related conditions is expected to expand treatment availability. The industry’s growth is reinforced by an increasing focus on patient well-being and early interventions that reduce the long-term impact of panic disorder.

Forecast

The panic disorder market forecast indicates steady expansion across the 7 major markets from 2025-2034. Starting at USD 9.70 Billion in 2024, the market is projected to achieve USD 14.61 Billion by 2034 at a CAGR of 4.18%. The United States is expected to dominate, driven by advanced healthcare infrastructure and high awareness levels. Europe will witness consistent growth due to government-backed mental health campaigns, while Japan is anticipated to emerge as a significant contributor owing to its increasing focus on psychiatric care. The future landscape will be shaped by personalized treatment approaches, AI-based therapy tools, and continuous innovation in drug formulations.

Competitor Analysis

The panic disorder market features a competitive landscape with leading pharmaceutical and biotechnology companies focusing on research and development, product innovation, and strategic collaborations to enhance their market share. Key players include:

• Teva Pharmaceutical Industries Ltd – Offers a wide range of psychiatric medicines with strong global distribution capabilities.
• Sun Pharmaceutical Industries Ltd. – Expands presence in generics and innovative psychiatry-focused medications.
• Mylan – Provides affordable mental health drugs with global reach and accessibility.
• AstraZeneca – Engages in research-driven psychiatric drug development and therapy innovations.
• Abbott – Focuses on advanced healthcare solutions with diverse mental health products.
• Baxter – Provides supportive care solutions and pharmaceuticals aiding mental health management.
• Bristol-Myers Squibb Company – Known for its strong pipeline of psychiatric and neurological treatments.
• Eli Lilly and Company – Offers innovative psychiatric medications improving patient outcomes globally.
• F. Hoffmann-La Roche Ltd – Invests heavily in neuroscience and mental health therapeutic research.
• GlaxoSmithKline plc – Provides a broad portfolio of anti-anxiety and antidepressant drugs.
• Recordati S.p.A. – Specializes in niche pharmaceutical therapies, including psychiatric treatments.
• Boehringer Ingelheim International GmbH – Strong research initiatives in neurological and psychiatric conditions.
• Neurocrine Biosciences, Inc – Focused on innovative drug development for mental and neurological disorders.
• Sanofi – Expands psychiatric care portfolio with advanced drug solutions worldwide.

Find More Report

CDMO Market: https://bit.ly/45yUr3r

Cancer Pain Market: https://bit.ly/46mIb77

DNA Microarray Market: https://bit.ly/46m6aU7